AA
SPRB

ALPS Advisors’s Spruce Biosciences SPRB Stock Holding History

ALPS Advisors’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-382
Closed -$172K – 989
2021
Q3 		$172K Sell
382
-28
-7% -$17.6K ﹤0.01% 904
2021
Q2 		$344K Buy
+410
New +$438K ﹤0.01% 725

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ALPS Advisors's SPRB Position: Q4 2021 in Review

ALPS Advisors sold out of Spruce Biosciences (SPRB) in Q4 2021, closing a stake of 382 shares — an estimated $172K sold.

ALPS Advisors first reported a position in SPRB in Q2 2021 and held it in 2 quarters. The position peaked at $344K in Q2 2021. 50 funds tracked by Wall St. Rank hold SPRB as of Q4 2021.

  • ALPS Advisors reported no remaining Spruce Biosciences position as of Q4 2021 after selling out during the quarter.
  • ALPS Advisors sold 382 Spruce Biosciences shares in Q4 2021, an estimated $172K.
  • ALPS Advisors first reported a position in Spruce Biosciences in Q2 2021 and held it in 2 quarters.
  • ALPS Advisors's Spruce Biosciences position peaked at $344K in Q2 2021.
  • 50 funds tracked by Wall St. Rank held Spruce Biosciences as of Q4 2021.

Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.